Skip to main content
Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc. — Investor Relations & Filings

Ticker · PCRX ISIN · US6951271005 LEI · 549300P56LERYBDHCF69 US Manufacturing
Open in API
Filings indexed 1,217 across all filing types
Latest filing 2018-08-16 Director's Dealing
Country US United States of America
Listing US PCRX

About Pacira BioSciences, Inc.

https://www.pacira.com/

Pacira BioSciences, Inc. is a pharmaceutical company that develops, commercializes, and manufactures non-opioid pain management and regenerative health solutions. The company's mission is to provide alternatives to opioids by delivering innovative, precise, and targeted therapies. Its products and research pipeline address a diverse range of needs, including postsurgical, chronic, and musculoskeletal pain. Pacira is also focused on developing advanced solutions, including gene therapy, to address unmet needs in pain management.

Recent filings

Filing Released Lang Actions
FORM 4 SUBMISSION
Director's Dealing
2018-08-16 English
FORM 4 SUBMISSION
Director's Dealing
2018-08-16 English
10-Q - PCRX - 6.30.18
Interim / Quarterly Report Q2 2018
2018-08-02 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Pacira Pharmaceuticals, Inc. It specifically includes an Item 2.02 titled 'Results of Operations and Financial Condition' and references an attached Exhibit 99.1 which is an earnings press release for the second quarter ended June 30, 2018. The text states that the press release is furnished as an exhibit and is not deemed filed for certain legal purposes, indicating this document is primarily an announcement of earnings results rather than the full earnings report itself. The document length is 3309 characters, which is relatively short and consistent with an earnings release announcement rather than a full detailed report. Therefore, the document should be classified as an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2018-08-02 English
8-K Q2 2018 REVENUE PRESS RELEASE
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated July 10, 2018, reporting preliminary net product sales for Q2 ended June 30, 2018. It includes a press release announcing financial results but does not contain detailed financial statements or comprehensive analysis. The document is relatively short (3355 characters) and primarily serves as an announcement of quarterly financial results. This matches the definition of an Earnings Release (ER), which is the initial announcement of quarterly/periodical financial results with key highlights only.
2018-07-10 English
FORM 4 SUBMISSION
Director's Dealing
2018-06-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.